Cedric Francois Sells 6,247 Shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $28.70, for a total value of $179,288.90. Following the completion of the sale, the chief executive officer now directly owns 307,415 shares in the company, valued at $8,822,810.50. This represents a 1.99 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Apellis Pharmaceuticals Stock Down 3.1 %

APLS traded down $0.90 on Tuesday, hitting $27.69. 1,676,758 shares of the company were exchanged, compared to its average volume of 2,547,033. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91. The company has a market cap of $3.44 billion, a price-to-earnings ratio of -13.64 and a beta of 0.94. The firm has a 50-day moving average price of $31.87 and a two-hundred day moving average price of $33.55. Apellis Pharmaceuticals, Inc. has a twelve month low of $24.34 and a twelve month high of $71.90.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The firm had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. During the same period last year, the business earned ($1.17) EPS. The firm’s revenue was up 78.3% compared to the same quarter last year. On average, equities analysts predict that Apellis Pharmaceuticals, Inc. will post -1.72 earnings per share for the current year.

Hedge Funds Weigh In On Apellis Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of APLS. Rhumbline Advisers boosted its holdings in Apellis Pharmaceuticals by 2.2% in the second quarter. Rhumbline Advisers now owns 123,565 shares of the company’s stock valued at $4,740,000 after purchasing an additional 2,644 shares in the last quarter. State of New Jersey Common Pension Fund D lifted its position in shares of Apellis Pharmaceuticals by 6.6% during the 2nd quarter. State of New Jersey Common Pension Fund D now owns 45,241 shares of the company’s stock worth $1,735,000 after buying an additional 2,820 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its holdings in shares of Apellis Pharmaceuticals by 46.7% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 12,754 shares of the company’s stock valued at $489,000 after buying an additional 4,060 shares in the last quarter. Envestnet Asset Management Inc. grew its position in shares of Apellis Pharmaceuticals by 42.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 134,536 shares of the company’s stock valued at $5,161,000 after buying an additional 39,931 shares during the last quarter. Finally, Edgestream Partners L.P. raised its stake in Apellis Pharmaceuticals by 240.4% during the 2nd quarter. Edgestream Partners L.P. now owns 54,572 shares of the company’s stock worth $2,093,000 after acquiring an additional 38,541 shares in the last quarter. Institutional investors and hedge funds own 96.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on APLS shares. Mizuho lowered their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating on the stock in a research report on Thursday, October 24th. Wells Fargo & Company reduced their price objective on Apellis Pharmaceuticals from $43.00 to $30.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Needham & Company LLC dropped their target price on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Royal Bank of Canada reiterated a “sector perform” rating and set a $25.00 price target on shares of Apellis Pharmaceuticals in a report on Monday, November 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $57.00 target price on shares of Apellis Pharmaceuticals in a report on Tuesday. Eight analysts have rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Apellis Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $46.65.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).